Tag

Pfizer

All articles tagged with #pfizer

business17 days ago•2 min saved

Nike taps Pfizer CFO Denton to lead finance in next growth phase

Nike announced that David M. Denton will join as Executive Vice President and Chief Financial Officer, effective August 17, succeeding Matthew Friend who will step down but stay through September 4 to ensure a smooth transition. Denton, currently CFO of Pfizer since 2022, has more than 30 years of finance leadership at companies including Lowe’s and CVS Health and prior board experience. Nike also updated on fourth-quarter/fiscal-2026 results (June 30); the report will include a one-time tariff-refund benefit and is expected to be broadly in line with prior guidance absent that benefit.

via About Nike|

#business #cfo-transition #denton

business18 days ago•2 min saved

Pfizer's New NSCLC ADC Flops in Phase 3, but Combinations Could Revive the Program

Pfizer’s first new ADC after acquiring Seagen failed to meet its primary endpoint in a phase 3 nonsquamous NSCLC trial, showing no significant overall survival advantage vs docetaxel. The company cites a stronger signal in a patient subgroup with one prior therapy and notes ongoing phase 3 studies combining sigvotatug vedotin with pembrolizumab in first-line NSCLC, sustaining optimism for the program despite the setback.

via Fierce Biotech|

#business #nsclc #pembrolizumab

business1 month ago•2 min saved

Pfizer's obesity drug shows potential with monthly dosing after weekly ramp

Mid-stage data from Pfizer’s obesity drug berobenatide (from Metsera) suggest dosing it monthly after an initial weekly period can sustain weight loss through 28 weeks, with up to 12.1% loss in patients who stayed on treatment, though the monthly pace lags Lilly’s Zepbound and competitive clarity remains uncertain.

via statnews.com|

#berobenatide #business #obesity

business1 month ago•2 min saved

Pfizer bets on monthly obesity shot as midstage data show Wegovy-like GI side effects

Pfizer presented midstage results for berobenatide, a monthly GLP-1 obesity drug acquired with Metsera for $10 billion, showing a side-effect profile similar to Novo Nordisk’s Wegovy (average nausea ~38%, vomiting ~23%). The long half-life makes monthly dosing front-loaded, and researchers plan a slower dose ramp in late-stage trials. Weight loss reached up to 12.3% in non-diabetics; analysts expect 20–25% vomiting and see monthly dosing as a potential differentiator from weekly rivals like Wegovy and Lilly’s Zepbound.

via Reuters|

#berobenatide #business #pfizer

technology1 month ago•2 min saved

Pfizer Taps Chai Discovery to Fast-Track AI-Designed Biologics

Chai Discovery announced a license with Pfizer to deploy its frontier AI platform, including the Chai-3 model and a Pfizer-custom model, within Pfizer’s drug discovery engine to accelerate biomolecule design and target hard-to-reach areas. Pfizer will gain early access to Chai-3, which advances antibody design and generalization, alongside a tailored model leveraging Pfizer’s data. The deal highlights growing use of AI in pharma to shorten discovery timelines that traditionally span months to weeks.

via Business Wire|

#ai-in-drug-discovery #antibody-design #biopharma

business1 month ago•2 min saved

Pfizer inks $10B pact with Innovent to fast-track 12 cancer drugs

Pfizer and Innovent announced a broad collaboration worth up to $10 billion to develop 12 cancer medicines, starting with a $650 million upfront and up to $9.85 billion in milestones. Pfizer will gain exclusive global licenses for four programs, ex-China rights to four, and co-develop four with Innovent, while Innovent handles eight programs through phase 1. The partners will co-commercialize jointly owned assets in the U.S. and Europe, illustrating how Western pharma is leveraging China’s rapid early development to boost productivity and global reach.

via Fierce Biotech|

#business #cancer-drugs #china-biotech

business1 month ago•15 min saved

Next-gen obesity drug race tightens as pivotal readouts loom

Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.

via Pharma Voice|

#business #eli-lilly #glp-1

business2 months ago•2 min saved

Pfizer Beats Q1 Expectations, Bets on Pipeline to Sustain 2026 Outlook

Pfizer beat Q1 2026 estimates with adjusted EPS of 75 cents and revenue of $14.45 billion, reaffirming its 2026 guidance as growth from newly launched and acquired drugs offsets declines in Covid vaccine and Paxlovid sales; the company is pursuing long-term pipeline investments, notably a $10 billion Metsera acquisition, with 2026 targets of about $2.80–$3.00 in adjusted EPS and $59.5–$62.5 billion in revenue.

via CNBC|

#business #eliquis #metsera

health3 months ago•12 min saved

RFK Jr.'s Lyme pledge collides with vaccine history as Pfizer pushes a new jab

RFK Jr., as HHS secretary, pledges stronger action on Lyme disease with better diagnostics and treatment, but his anti-vaccine stance complicates Pfizer/Valneva’s plan to file a Lyme vaccine—the first in more than two decades. The prior Lyme vaccine Lymerix faced safety questions and weak uptake, illustrating the challenges Pfizer now faces, even as Lyme incidence rises with climate-driven tick expansion and researchers pursue vaccines and other preventive tools.

via CNN|

#health #lyme-disease #lymerix

health3 months ago•5 min saved

New Four-Dose Lyme Vaccine Shows About 70% Protection

Pfizer and Valneva announced phase 3 results for PF-0730740, a four-dose Lyme disease vaccine that achieved about 70% efficacy in preventing infection among people aged 5+ across the US, Canada, and Europe. The regimen requires four injections (two two months apart, then months five–nine, then one year later) and the vaccine is not yet approved; its impact on disease complications is unknown, but it could offer meaningful protection for those in endemic areas while continued tick-prevention steps remain important.

via Women's Health|

#health #lyme-disease #pfizer

health3 months ago•4 min saved

Lyme Vaccine Delivers Promising 70%+ Protection in Major Trial, Heads to FDA Review

Pfizer and Valneva’s VALOR Phase III trial for PF-07307405 shows about 73% efficacy at preventing confirmed Lyme disease, but the primary endpoint's 95% confidence interval is wide (15.8%–93.5%), likely due to milder Lyme activity during the study; a separate analysis confirms the lower bound above 20%, supporting FDA-approval steps. The vaccine targets the OspA protein to block Borrelia burgdorferi in ticks, and if approved could significantly boost Lyme prevention for high-risk groups.

via Gizmodo|

#clinical-trial #health #lyme-disease

health3 months ago•2 min saved

Pfizer-Valneva Lyme vaccine shows strong protection but misses statistical bar

An experimental Lyme vaccine from Pfizer and Valneva reduced the risk of Lyme disease by more than 70% in a trial, but it reportedly missed a key statistical endpoint, prompting regulators to scrutinize potential approval amid ongoing debates over trial methods and Lyme prevention.

via statnews.com|

#health #lyme-disease #pfizer

health3 months ago•2 min saved

Lyme vaccine shows strong efficacy in late-stage results but misses primary endpoint

Pfizer and Valneva's Lyme disease vaccine posted 73.2% efficacy starting 28 days after the fourth dose in a late-stage trial, but the study missed its primary endpoint under the worst-case scenario (15.8% efficacy in the initial analysis); a second analysis showed 74.8% efficacy, leading to plans for regulatory submissions, with no Lyme vaccine currently approved.

via NBC News|

#clinical-trial #health #lyme-disease

business3 months ago•2 min saved

Pfizer pushes ahead with Lyme vaccine despite late-stage trial miss

Pfizer intends to seek FDA approval for its Lyme disease vaccine candidate even after a late-stage trial failed to meet statistical goals due to too few Lyme cases; the company says efficacy exceeded 70% in vaccine recipients versus placebo, which they consider strong enough to move forward. Partner Valneva projects up to $1 billion in peak annual sales. The Phase 3 study started with about 18,000 participants but was reduced to roughly 9,400 due to site-quality issues, and Pfizer reports no safety concerns; the vaccine requires three initial doses followed by a booster and targets the outer surface protein A of the bacteria.

via CNBC|

#business #lyme-disease #pfizer

healthcare5 months ago•1 min saved

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

via Axios|

#costplusdrugs #drug-pricing #generics